Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is based in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: synaptogen.com
PRE 14A - Synaptogenix, Inc. (0001571934) (Filer)
EFFECT - Synaptogenix, Inc. (0001571934) (Filer)
S-3 - Synaptogenix, Inc. (0001571934) (Filer)
8-K - Synaptogenix, Inc. (0001571934) (Filer)
D - Synaptogenix, Inc. (0001571934) (Filer)
8-K - Synaptogenix, Inc. (0001571934) (Filer)
8-K - Synaptogenix, Inc. (0001571934) (Filer)
8-K - Synaptogenix, Inc. (0001571934) (Filer)
10-Q - Synaptogenix, Inc. (0001571934) (Filer)
8-K - Synaptogenix, Inc. (0001571934) (Filer)
New Patent Issued Covering Treatment Of Neurodegenerative Diseases; Studies To Compare Analogs With Bryostatin In SCI
Maxim Group analyst Jason McCarthy upgrades Synaptogenix (NASDAQ:SNPX) from Hold to Buy and announces $14 price target.
https://ppubs.uspto.gov/pubwebapp/external.html?q=(12016837).pn
Gainers Lantern Pharma (NASDAQ:LTRN) shares rose 14.3% to $7.04 during Friday's after-market session. The company's market cap stands at $75.7 million. As per the press release, Q1 earnings came out yesterday. Vaccinex (NASDAQ:VCNX) shares moved upwards by 7.82% to $6.2. The market value of their outstanding shares is at $9.8 million. Purple Biotech (NASDAQ:PPBT) shares increased by 7.44% to $0.55. The market value of their outstanding shares is at $14.3 million. Dominari Holdings (NASDAQ:DOMH) stock moved upwards by 5.21% to $2.22. The company's market cap stands at $13.1 million. Alterity Therapeutics (NASDAQ:ATHE) stock increased by 4.97% to $2.11. The market value of their outstandi
Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on April 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) ("Listing Rule") for continued listing on The Nasdaq Capital Market.On April 24, 2023, Synaptogenix received notice from the Listing Qualifications Department of Nasdaq indicating that the Company was not in compliance with the Listing Rule, as its common stock had failed to meet a closing bid price of
Gainers IN8bio (NASDAQ:INAB) stock increased by 47.7% to $1.61 during Wednesday's pre-market session. The market value of their outstanding shares is at $69.6 million. Jaguar Health (NASDAQ:JAGX) shares rose 25.0% to $0.11. The company's market cap stands at $31.0 million. China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 24.85% to $2.16. The market value of their outstanding shares is at $1.2 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by 23.06% to $1.39. The market value of their outstanding shares is at $5.6 million. iSpecimen (NASDAQ:ISPC) stock increased by 13.96% to $0.24. The company's market cap stands at $2.1 million. Akebia Therapeutics (NASDAQ
According to its most recent 10-K filing as of December 31, 2023, Synaptogenix reported a cash balance of $28.7 million. Additionally, following a recent reverse split, the Company now has approximately 1,085,333 outstanding shares.
Synaptogenix Inc (NASDAQ:SNPX) shares are trading slightly higher Thursday morning after the company announced a 1-for-25 reverse stock split. This move aims to increase the per-share trading price to meet Nasdaq’s minimum bid price requirement. The reverse split will occur on Thursday with trading on a split-adjusted basis starting on Friday. The reverse split will uniformly affect all shareholders and reduce outstanding shares from 27,133,349 to about 1,085,333, with proportional adjustments made for equity awards, convertible preferred stock, and warrants. See Also: HubSpot Stock Jumps As Alphabet Considers Acquisition Offer: The Details How To Buy SNPX Stock Besides going
Conference Call to be held Tuesday, July 26th at 4:30pm ET NEW YORK, July 26, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced changes to its Scientific Advisory Board (SAB) in preparation for Phase 2 data from its Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe Alzheimer's disease (AD). The SAB is comprised of industry and academic leaders in science and drug development and will be instrumental in the further development of the Company's regenerative therapies across AD, Fragile X syndrome,
NEW YORK, July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it will hold a corporate update conference call for investors. The call will take place on Tuesday, July 26th at 4:30pm ET and will be hosted by the Company's Chief Executive Officer, Dr. Alan Tuchman, and its President and Chief Science Officer, Dr. Daniel Alkon. Drs. Tuchman and Alkon will also take live Q&A following their prepared remarks. The U.S. toll free dial-in for the conference call is (877) 407-8293, and the international dial-in number is 1-(201) 689-8349. Fo
NEW YORK, July 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract for presentation at the Alzheimer's Association International Conference (AAIC) is now available entitled "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease (AD) Patients: A Regenerative Therapeutic Strategy." "Recent further analyses of pre-specified cohort results revealed clear evidence of Bryostatin therapeutic efficacy for advanced AD patients. Analyses of treatment benefit, based on mean differences and as a function of successive dosing in
NEW YORK, July 21, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it will hold a conference call for investors to discuss its abstract presented at the Alzheimer's Association International Conference. The call will take place on Monday, July 26th at 4:15pm ET and will be hosted by the Company's Chief Executive Officer, Dr. Alan Tuchman, and its President and Chief Science Officer, Dr. Daniel Alkon. Drs. Tuchman and Alkon will take live Q&A following their prepared remarks. The U.S. toll free dial-in for the conference call is (877) 407-9205, and the internationa
Supports IP development for novel mushroom genetics and therapeutics for multiple indications NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics. Cannasoul is founded by the Technion Research & Develo
Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel L. Alkon, M.D., was honored by the International Association of Biomedical Sciences for his presentation at the University of Southern California-sponsored IABS Forum-2023, a gathering of world-renowned neuroscientists and academics discussing "New Concepts for the Treatment of Neurodegenerative
Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new directors to its board. Jonathan Schechter, Partner, The Special Equities Group, and Robert Weinstein, Chief Financial Officer, Synaptogenix, Inc. have joined Oblong's board of directors. In addition, Jim Lusk and Matthew Blumberg have retired from the Oblong board. "We're delighted to welcome Jonathan and Robert to the Oblong board of directors," said Pete Holst, President and CEO. "Both individuals bring a wealth of knowledge in mergers and acquisitions, digital transfor
NEW YORK, Sept. 11, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0 million financing with existing investors involving the sale of 5,000 shares of its newly issued Series C convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible into shares of its common stock in a registered public offering (the "Registered Offering") and a concurrent private placement (the "Private Placement" and collectively with the Registered
Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs New patent covers proprietary analogs in the treatment of neurodegenerative diseases NEW YORK, July 18, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new collaboration agreement with LSU Health New Orleans' Neuroscience Center of Excellence for pre-clinical testing of the Company's polyunsaturated fatty acid (PUFA) analogs as a treatment for spinal cord injury (SCI). The Company also announced that the US Patent and Trademark Office (USPTO) recently issu
Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK, June 26, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that the Food & Drug Administration (FDA) has authorized an Investigational New Drug (IND) application for Bryostatin-1 as a potential treatment for multiple sclerosis (MS). The fully-funded, open-label clinical trial will be held and managed at Cleveland Clinic Neurological Institute's Mellen Center for Multiple Sclerosis. The study will utilize state-of-the-ar
Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways NEW YORK, May 7, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today applauds the reported move by the U.S. Drug Enforcement Agency (the "DEA") to recommend reclassifying cannabis as a Schedule III drug, and announces potential benefits of the rescheduling to its partner Cannasoul Analytics ("Cannasoul"), founded by the Technion-Israel Institute of Technology, in its discovery of cannabis-based therapeutics. As reported in the pre
NEW YORK, April 24, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on April 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) ("Listing Rule") for continued listing on The Nasdaq Capital Market. On April 24, 2023, Synaptogenix received notice from the Listing Qualifications Department of Nasdaq indicating that the Company was not in compliance with the Listing Rule, as its common stock
Supports IP development for novel mushroom genetics and therapeutics for multiple indications NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics. Cannasoul is founded by the Technion Research & Develo
Common stock will begin trading on split-adjusted basis on April 5, 2024 NEW YORK, April 3, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 25 pre-split shares. The reverse stock split will become effective at 5:00 p.m. Eastern Standard Time on Thursday, April 4, 2024. SNPX common stock will continue to be traded on The Nasdaq Capital Market under the symbol SNPX and will begin trading on a split-adjusted basis when the market opens
Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel L. Alkon, M.D., was honored by the International Association of Biomedical Sciences for his presentation at the University of Southern California-sponsored IABS Forum-2023, a gathering of world-renowned neuroscientists and academics discussing "New Concepts for the Treatment of Neurodegenerative
Presenters, including Nobel Laureate in Medicine, to discuss innovative treatments for neurodegeneration Company to feature lead therapeutic's statistically significant benefits, p < 0.007, for severe Alzheimer's disease (AD) patients NEW YORK, Dec. 6, 2023 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel Alkon, M.D., will join more than 30 leading neuroscientists and academics as a speaker at IABS Forum-2023, "New Concepts for the Treatment of Neurodegenerative Disorders." The distinguished
Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK, Sept. 26, 2023 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a peer-reviewed publication of statistically significant integration of secondary and exploratory endpoint data from its previously completed Phase 2 trial of Bryostatin-1 for Alzheimer's disease. The paper, titled "Advanced Alzheimer's Disease (AD) Patients Show Safe, Significant, and Persistent Benefit in 6 Month Bryostatin Trial," will appear in
SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)
SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)
SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)
SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)
SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)
SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)
SC 13G - Synaptogenix, Inc. (0001571934) (Subject)
SC 13G - Synaptogenix, Inc. (0001571934) (Subject)
4 - Synaptogenix, Inc. (0001571934) (Issuer)
4 - Synaptogenix, Inc. (0001571934) (Issuer)
4 - Synaptogenix, Inc. (0001571934) (Issuer)
4 - Synaptogenix, Inc. (0001571934) (Issuer)
4 - Synaptogenix, Inc. (0001571934) (Issuer)
4 - Synaptogenix, Inc. (0001571934) (Issuer)
4 - Synaptogenix, Inc. (0001571934) (Issuer)
4 - Synaptogenix, Inc. (0001571934) (Issuer)
4 - Synaptogenix, Inc. (0001571934) (Issuer)
4 - Synaptogenix, Inc. (0001571934) (Issuer)